Donepezil, rivastigmine, galantamine and memantine for ...

158
References
120. Kavanagh S, Schneider J, Knapp M, Beecham J,
Netten A. Elderly people with dementia: cost
effectiveness and balance of care. In Knapp M,
editor. The economic evaluation of mental health care.
Aldershot: Arena; 1995. pp. 125–56.
121. Stewart A. Costs of care for people with dementia aged
75 and over. Discussion paper 1303/2. University of
Kent, Canterbury: PSSRU; 1997.
122. Wolstenholme J, Fenn P, Gray A, Keene J, Jacoby
R, Hope T. Estimating the relationship between
disease progression and cost of care in dementia.
Br J Psychiatry 2002;181:36–42.
123. Bowie P, Branton T, Holmes J. Should the mini
mental state examination be used to monitor
dementia treatments? Lancet 1999;354:1527–8.
124. Davey RJ, Jamieson S. The validity of using the
mini mental state examination in NICE dementia
guidelines. J Neurol Neurosurg Psychiatry 2004;
75:343–4.
125. Tombaugh TN, Mcintyre NJ. The mini-mentalstate-examination
– a comprehensive review. J Am
Geriatr Soc 1992;40:922–35.
126. Gray A, Fenn P. Alzheimer’s disease: the burden of
the illness in England. Health Trends 1993;25:31–7.
127. Monitoring alzheimer’s disease in nursing homes.
046/911. London: Taylor Nelson AGB; 1997.
128. Mendiondo MS, Ashford JW, Kryscio RJ, Schmitt
FA. Modelling mini mental state examination
changes in Alzheimer’s disease. Stat Med 2000;
19:1607–16.
129. Martin DC, Miller JK, Kapoor W, Arena VC,
Boller F. A controlled study of survival with
dementia [published erratum appears in Arch
Neurol 1988;45:619]. Arch Neurol 1987;44:1122–6.
130. Netten A, Darton R, Bebbington A, Forder J,
Brown P, Mummery K. Residential and nursing
home care of elderly people with cognitive
impairment: prevalence, mortality and costs. Aging
Ment Health 2001;5:14–22.
131. Caro JJ, Getsios D, Migliaccio-Walle K, Raggio G,
Ward A. Assessment of health economics in
Alzheimer’s disease (AHEAD) based on need for
full-time care. Neurology 2001;57:964–71.
132. Stern Y, Tang MX, Albert MS, Brandt J,
Jacobs DM, Bell K, et al. Predicting time to
nursing home care and death in individuals with
Alzheimer disease. JAMA 1997;277:806–12.
133. Richards M, Marder K, Bell K, Dooneief G,
Mayeux R, Stern Y. Interrater reliability of
extrapyramidal signs in a group assessed for
dementia. Arch Neurol 1991;48:1147–9.
134. Martin J, Meltzer H, Elliot D. The prevalence of
disability among adults: OPCS surveys of disability in
Great Britain Report 1. London: HMSO; 1988.
135. Doraiswamy PM, Bieber F, Kaiser L, Krishnan KR,
Reuning-Scherer J, Gulanski B. The Alzheimer’s
Disease Assessment Scale: patterns and predictors
of baseline cognitive performance in multicenter
Alzheimer’s disease trials. Neurology 1997;
48:1511–17.
136. Clegg A, Bryant J, Nicholson T, McIntyre L,
De Broe S, Gerard K, et al. Clinical and costeffectiveness
of donepezil, rivastigmine, and
galantamine for Alzheimer’s disease. A systematic
review. Int J Technol Assess Health Care 2002;
18:497–507.
137. Husereau D, Wolfson C, Shukla V. Drug treatments
for Alzheimer’s disease: efficacy, outcome
measurements and cost effectiveness. Technol
Overview 2001;(4).
138. Small GW, Donohue JA, Brooks RL. An economic
evaluation of donepezil in the treatment of
Alzheimer’s disease. Clin Ther 1998;20:838–50.
139. Fillit H, Gutterman EM, Lewis B. Donepezil use in
managed Medicare: effect on health care costs and
utilization. Clin Ther 1999;21:2173–85.
140. Lanctot K, Risebrough N, I. Factors affecting the
economic attractiveness of cognitive enhancers in
Alzheimer’s disease. Annual Meeting of the
Canadian Society for Clinical Investigation, the
Royal College of Physicians and Surgeons of
Canada and Participating Societies Toronto,
Ontario, Canada, September 1998. Clin Invest Med
1998;24–27(Suppl):S17.
141. Tariot P, Federoff HJ. Current treatment for
Alzheimer disease and future prospects. Alzheimer
Dis Assoc Disord 2003;17(Suppl 4):S105–113.
142. Mackell JA, Ferris SH, Mohs R, Schneider L,
Galasko D, Whitehouse P, et al. Multicenter
evaluation of new instruments for Alzheimer’s
disease clinical trials: summary of results. The
Alzheimer’s Disease Cooperative Study. Alzheimer
Dis Assoc Disord 1997;11:Suppl-9.
143. Rahkonen T, Eloniemi-Sulkava U, Rissanen S,
Vatanen A, Viramo P, Sulkava R. Dementia with
Lewy bodies according to the consensus criteria in
a general population aged 75 years or older.
J Neurol Neurosurg Psychiatry 2003;74:720–4.
144. Paton J, Johnston K, Katona C, Livingston G. What
causes problems in Alzheimer’s disease: attributions
by caregivers. Int J Geriatr Psychiatry in press.
145. Kronborg Andersen C, Sogaard J, Hansen E,
Kragh-Sorensen A, Hastrup L, Andersen J, et al.
The cost of dementia in Denmark: the Odense
Study. Dement Geriatr Cogn Disord 1999;10:295–304.
146. Livingston G, Katona C, Roch B, Guilhame C,
Rive B. A dependency model for patients with
Alzheimer’s disease: its validation and relationship
to the costs of care – the LASER-AD Study. Curr
Med Res Opin 2004;S7:1007–16.
147. Wimo A, Winblad B, Stoffler A, Wirth Y,
Mobius HJ. Resource utilisation and cost analysis